Skip to main content
SpringerLink
Log in

Levels of Soluble CD40 Ligand and P-Selectin in Nonalcoholic Fatty Liver Disease

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Nonalcoholic fatty liver disease (NAFLD) is linked to an increased risk of cardiovascular disease. We aimed to research whether the levels of soluble P-selectin (sP-selectin) and soluble CD40 ligand (sCD40L), markers of endothelial function, are altered in subjects with NAFLD having no confounding factors for atherosclerosis. sCD40L, sP-selectin, and high-sensitivity C-reactive protein (hsCRP) levels, and homeostasis model assessment of insulin resistance (HOMA-IR) indexes were measured in 50 NAFLD subjects and 30 healthy controls. sCD40L, sP-selectin, and hsCRP levels were not significantly different between two groups (P = 0.48, 0.51, and 0.34, respectively). Body mass index, waist circumference, and insulin levels and HOMA indexes were significantly higher in subjects with NAFLD (all P < 0.001). The present data show that sCD40L and sP-selectin may not contribute to the accelerated atherogenesis associated with this clinically relevant condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: A clinical review. Dig Dis Sci. 2005;50:171–180. doi:10.1007/s10620-005-1267-z.

    Article  PubMed  Google Scholar 

  2. Preiss D, Sattar N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115:141–150. doi:10.1042/CS20070402.

    Article  CAS  Google Scholar 

  3. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007;11:105–117. doi:10.1016/j.cld.2007.02.013.

    Article  PubMed  Google Scholar 

  4. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon? Diabetologia. 2008;51:1947–1953. doi:10.1007/s00125-008-1135-4.

    Article  CAS  PubMed  Google Scholar 

  5. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Dia Med. 2005;22:1354–1358. doi:10.1111/j.1464-5491.2005.01646.x.

    Article  CAS  Google Scholar 

  6. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72–78. doi:10.1016/j.amjmed.2007.08.041.

    Article  PubMed  Google Scholar 

  7. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203:581–586.

    Article  CAS  PubMed  Google Scholar 

  8. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–2121. doi:10.2337/dc07-0349.

    Article  CAS  PubMed  Google Scholar 

  9. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–240. doi:10.1016/j.atherosclerosis.2006.08.021.

    Article  CAS  PubMed  Google Scholar 

  10. Phipps RP. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA. 2000;97:6930–6932. doi:10.1073/pnas.97.13.6930.

    Article  CAS  PubMed  Google Scholar 

  11. Garlichs CD, John S, Schmeisser A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104:2395–2400. doi:10.1161/hc4501.099312.

    Article  CAS  PubMed  Google Scholar 

  12. Aukrust P, Müller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614–620.

    CAS  PubMed  Google Scholar 

  13. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones. Circulation. 2003;107:2664–2669. doi:10.1161/01.CIR.0000074043.46437.44.

    Article  CAS  PubMed  Google Scholar 

  14. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266–2268. doi:10.1161/hc4401.099447.

    Article  PubMed  Google Scholar 

  15. Wagner DD. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb Haemost. 1993;70:105–110.

    CAS  PubMed  Google Scholar 

  16. Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: İmplications for atherogenesis? A preliminary report. J Hypertens. 1995;13:1674–1678.

    CAS  PubMed  Google Scholar 

  17. Davì G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97:953–957.

    PubMed  Google Scholar 

  18. Blann AD, Dobrotova M, Kubisz P, McCollum CN. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626–630.

    CAS  PubMed  Google Scholar 

  19. Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation. 1995;92:1693–1696.

    CAS  PubMed  Google Scholar 

  20. Sakurai S, Inoue A, Koh CS, Owa M, Yanagisawa N. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med. 1997;2:163–168.

    CAS  PubMed  Google Scholar 

  21. Shimomura H, Ogawa H, Arai H, et al. Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. Am J Cardiol. 1998;81:397–400. doi:10.1016/S0002-9149(97)00945-4.

    Article  CAS  PubMed  Google Scholar 

  22. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495.

    CAS  PubMed  Google Scholar 

  23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

    CAS  PubMed  Google Scholar 

  24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi:10.1007/BF00280883.

    Article  CAS  PubMed  Google Scholar 

  25. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63. doi:10.2337/diacare.23.1.57.

    Article  CAS  PubMed  Google Scholar 

  26. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis. 2001;21:3–16. doi:10.1055/s-2001-12925.

    Article  CAS  PubMed  Google Scholar 

  27. Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006;18:175–180. doi:10.1097/00042737-200602000-00010.

    Article  CAS  PubMed  Google Scholar 

  28. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: Role of visceral fat accumulation. Diabetes Care. 2004;27:2498–2500. doi:10.2337/diacare.27.10.2498.

    Article  PubMed  Google Scholar 

  29. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–1050. doi:10.1161/01.ATV.0000160613.57985.18.

    Article  CAS  PubMed  Google Scholar 

  30. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–480. doi:10.1002/hep.20781.

    Article  PubMed  Google Scholar 

  31. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutr Metab Cardiovasc Dis. 2007;17:684–698. doi:10.1016/j.numecd.2007.01.007.

    Article  CAS  PubMed  Google Scholar 

  32. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:41–43.

    Google Scholar 

  33. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92:4342–4346. doi:10.1073/pnas.92.10.4342.

    Article  CAS  PubMed  Google Scholar 

  34. Kornbluth RS, Kee K, Richman DD. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci USA. 1998;95:5205–5210. doi:10.1073/pnas.95.9.5205.

    Article  CAS  PubMed  Google Scholar 

  35. Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999;104:1041–1050. doi:10.1172/JCI6993.

    Article  CAS  PubMed  Google Scholar 

  36. Denger S, Jahn L, Wende P, et al. Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: Induction of the synthetic phenotype: A possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis. 1999;144:15–23. doi:10.1016/S0021-9150(99)00033-7.

    Article  CAS  PubMed  Google Scholar 

  37. Mach F, Schönbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–399.

    CAS  PubMed  Google Scholar 

  38. Schönbeck U, Mach F, Sukhova GK, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000;156:7–14.

    PubMed  Google Scholar 

  39. Semb AG, van Wissen S, Ueland T, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Down regulatory effect of statin therapy. J Am Coll Cardiol. 2003;41:275–279. doi:10.1016/S0735-1097(02)02718-3.

    Article  CAS  PubMed  Google Scholar 

  40. Gokulakrishnan K, Deepa R, Mohan V. Soluble P selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism. 2006;55:237–242. doi:10.1016/j.metabol.2005.08.019.

    Article  CAS  PubMed  Google Scholar 

  41. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells. 1990;16:73–80.

    CAS  PubMed  Google Scholar 

  42. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: Vascular adhesion molecules. FASEB J. 1995;9:866–873.

    CAS  PubMed  Google Scholar 

  43. Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest. 1986;78:130–137. doi:10.1172/JCI112542.

    Article  CAS  PubMed  Google Scholar 

  44. McEver RP. GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem. 1991;45:156–161. doi:10.1002/jcb.240450206.

    Article  CAS  PubMed  Google Scholar 

  45. Parmentier S, McGregor L, Catimel B, Leung LL, McGregor JL. Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PADGEM). Blood. 1991;77:1734–1739.

    CAS  PubMed  Google Scholar 

  46. Blann AD, Lip GYH. Hypothesis: Is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128:135–138. doi:10.1016/S0021-9150(96)05980-1.

    Article  CAS  PubMed  Google Scholar 

  47. Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction. A new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis. 1997;8:383–390. doi:10.1097/00001721-199710000-00002.

    Article  CAS  PubMed  Google Scholar 

  48. Blann AD, Seigneur M, Boisseau MR, Taberner DA, McCollum CN. Soluble P selectin in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinolysis. 1996;7:789–793. doi:10.1097/00001721-199611000-00008.

    Article  CAS  PubMed  Google Scholar 

  49. Aller R, de Luis DA, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dsi Sci. 2008;53:1088–1092. doi:10.1007/s10620-007-9981-3.

    Article  CAS  Google Scholar 

  50. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–455. doi:10.1016/S0002-9343(99)00271-5.

    Article  CAS  PubMed  Google Scholar 

  51. Lizardi-Cervera J, Chavez-Tapia NC, Pérez-Bautista O, Ramos MH, Uribe M. Association among C-reactive protein, fatty liver disease, and cardiovascular risk. Dig Dis Sci. 2007;52:2375–2379. doi:10.1007/s10620-006-9262-6.

    Article  CAS  PubMed  Google Scholar 

  52. Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19:694–698. doi:10.1111/j.1440-1746.2004.03362.x.

    Article  CAS  PubMed  Google Scholar 

  53. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, González R, Alvarez M, Hernández V, García-Zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29:82–88.

    Article  CAS  PubMed  Google Scholar 

  54. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007;30:387–394. doi:10.1291/hypres.30.387.

    Article  CAS  PubMed  Google Scholar 

  55. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877–883.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Gulhane School of Medicine, Etlik, Ankara, Turkey

    Cemal Nuri Ercin, Teoman Dogru, Zeki Yesilova, Ahmet Uygun, Mustafa Gulsen & Sait Bagci

  2. Department of Biochemistry, Gulhane School of Medicine, Etlik, Ankara, Turkey

    Serkan Tapan & M. Kemal Erbil

  3. Department of Pathology, Gulhane School of Medicine, Etlik, Ankara, Turkey

    Yıldırım Karslioglu

  4. Department of Internal Medicine, Gulhane School of Medicine, Etlik, Ankara, Turkey

    Cem Haymana

  5. Department of Epidemiology, Gulhane School of Medicine, Etlik, Ankara, Turkey

    Selim Kilic

  6. Department of Endocrinology, Gulhane School of Medicine, Etlik, Ankara, Turkey

    Alper Sonmez

Authors
  1. Cemal Nuri Ercin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teoman Dogru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serkan Tapan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yıldırım Karslioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cem Haymana
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Selim Kilic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alper Sonmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zeki Yesilova
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ahmet Uygun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mustafa Gulsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sait Bagci
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. Kemal Erbil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teoman Dogru.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ercin, C.N., Dogru, T., Tapan, S. et al. Levels of Soluble CD40 Ligand and P-Selectin in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 55, 1128–1134 (2010). https://doi.org/10.1007/s10620-009-0817-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-009-0817-1

Keywords

Search

Navigation